Table 1 Demographic data
Category | Group I No LV perfusion defect or wall motion abnormality (n = 232) | Group II LV perfusion defect present, no wall motion abnormality (n = 28) | Group III LV perfusion defect and wall motion abnormality present (n = 18) | p-value* |
|---|---|---|---|---|
Age (years) | 68 ± 8 | 70 ± 9 | 69 ± 8 | 0.32 |
Men (%) | 110 (47%) | 14 (50%) | 14 (78%) | 0.046 |
Race/Ethnicity | Â | Â | Â | 0.50 |
Caucasian | 171 (74%) | 23 (82%) | 16 (89%) | Â |
African Am. | 56 (24%) | 4 (14%) | 2 (11%) | Â |
Hispanic | 2 (1%) | 1 (4%) | 0 (0%) | Â |
Asian | 3 (1%) | 0 (0%) | 0 (0%) | Â |
Body mass index (m/kg2) | 30.4 (6.5) | 30.3 (4.8) | 32.1 (5.4) | 0.54 |
Hypertension | 203 (88%) | 27 (96%) | 16 (89%) | 0.38 |
Coronary artery disease | 57 (25%) | 9 (32%) | 8 (44%) | 0.14 |
Prior MI | 16 (7%) | 5 (17%) | 3 (18%) | 0.05 |
Prior revascularization (PCI or CABG) | 31 (13%) | 9 (32%) | 8 (44%) | <0.001 |
Diabetes | 94 (41%) | 11 (39%) | 8 (44%) | 0.94 |
Hypercholesterolemia | 152 (70%) | 22 (79%) | 12 (86%) | 0.30 |
Smoking | 90 (42%) | 10 (36%) | 6 (43%) | 0.79 |
Medications | Â | Â | Â | Â |
Angiotensin converting enzyme inhibitor | 99 (43%) | 15 (54%) | 7 (39%) | 0.52 |
Angiotensin receptor blocker | 64 (30%) | 5 (18%) | 3 (20%) | 0.30 |
Statin | 152 (66%) | 21 (75%) | 14 (78%) | 0.37 |
Beta blocker | 99 (43%) | 13 (46%) | 11 (61%) | 0.32 |
Calcium channel antagonist | 68 (30%) | 8 (29%) | 9 (50%) | 0.20 |